Indices of hepatic steatosis and fibrosis in prediabetes and association with diabetes development in the vitamin D and type 2 diabetes study.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

Non-alcoholic fatty liver disease (NAFLD) is a common comorbidity that leads to poor outcomes in people at high risk for development of type 2 diabetes (T2D).

Vitamin D is a possible mediator.

In the vitamin D and type 2 diabetes study (D2d), the researchers investigated the relationship of baseline indices of NAFLD with incident T2D and whether the effect of vitamin D on diabetes was modified by NAFLD.

Who Took Part

The abstract describes 3972 individuals taking part.

How the Study Was Run

The researchers set it up as a randomized and placebo-controlled study.

The individuals were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.

Cross-sectional associations of indices of NAFLD with glycemia and vitamin D status were assessed in 3972 individuals screened for the D2d study.

In those with prediabetes randomized to vitamin D or placebo (n = 2423), the researchers examined longitudinal associations of NAFLD indices with incident T2D.

What Was Measured

PubMed files the paper under topics including Non-alcoholic Fatty Liver Disease, Diabetes Mellitus, Type 2, Prediabetic State, Liver Cirrhosis, Cross-Sectional Studies, Fibrosis and Vitamin D.

The authors tagged it with the keywords APRI, FIB-4, HSI, NAFLD and NAFLD-LFS.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 3972 individuals.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2023 (Journal of diabetes and its complications), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.